Rigas Austrumu kliniska universitates slimnica SIA — Clinical Trial Site

52 Registered trials

13 Currently recruiting

Organisation

Rigas Austrumu kliniska universitates slimnica SIA

Location

Riga, Latvia

Identifier

ORG-100030603

Address

Hipokrata Iela 4, 1079, Latvia

Departments

-
#7301
6202
8008
Cardiology
Cardiology department
clinic “Gailezers”
Clinic Gaiļezers
Clinic of Internal Diseases
Clinic of neurology and neurosurgery
Clinic of Urology and Oncologic Urology
Clinical Centre "Bikernieki"
Clinical Centre "Bikernieki", Ophthalmology Clinic
Department of Cardiology
Department of Pulmonology
Gailezers
Gynecology clinic
Latvia Oncology center
Latvia Oncology center
Latvian Oncology center
Latvian Oncology Centre
LV10007
N/A
NA
Neurology and neurosurgery
None
not applicable
Oncology
Oncology center
Oncology Clinic
Ophthalmology clinic
Ophthalmology clinic Biķernieki, Lielvārdes street 68, Riga, LV-1006, Latvia.
University Hospital and Oncology Centre
Urologijas un onkologiskas urologijas klinika
Urology unit

Clinical trials at this site (52)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
DAREON®-Lung-1: A study in people with advanced small cell lung cancer to compare obrixtamig plus atezolizumab, carboplatin, and etoposide t… Recruiting

2025-520565-51-00 small cell lung cancer 5 2026-06-23
A Phase 3 Single-arm Study of UGN-104 for the Treatment of LG-UTUC Recruiting

2024-519343-15-00 Low-grade Upper Tract Urothelial Cancer 5 2025-10-08
A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting

2024-514459-14-00 Non-Small Cell Lung Cancer 4 2025-04-22
A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age … Recruiting

2024-514801-69-00 Thyroid Eye Disease 4 2025-04-02
Therapeutic equivalence of CHF5993 pMDI 100/6/12.5 µg HFA-152a in subjects with mild to moderate asthma (TRECONY) Recruiting

2025-521456-35-00 Mild to moderate asthma 4 2026-04-13
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial of a Single Intravitreal Injection of 4D-150 in Adults with Macular Neovascula… Recruiting

2025-521349-25-00 Macular neovascularization secondary to age-related mac 5 2025-12-09
A phase III, randomized, open-label, blinded endpoint, comparative trial of ferric derisomaltose versus no intravenous iron in iron-deficien… Recruiting

2024-519059-28-00 Chronic Heart Failure 5 2025-07-17
202301CPC Redefine-HF Recruiting

2023-508581-15-00 Heart condition 5 2024-10-08
LSTA1 for subjects with newly diagnosed Glioblastoma Multiforme when added to standard of care (temozolomide) versus temozolomide Recruiting

2023-506813-23-00 Glioblastoma Multiforme 4 2023-12-18
Mifepristone and Letrozole in Ectopic Pregnancy (MILE) Recruiting

2023-503935-16-00 Ectopic pregnancy 4 2023-12-15
A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab… Recruiting

2023-503224-66-00 Atrial Fibrillation 5 2023-10-31
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting

2023-505438-85-00 Acute myocardial infarction (AMI) 5 2022-01-12
Extension Study for Participants in Studies That Include Pembrolizumab Recruiting

2022-501254-10-00 Advanced tumors 5 2018-08-24
A Phase 3 Single-arm Study of UGN-103 for the Treatment of LG IR NMIBC. Ended

2023-507261-25-00 Nonmuscle Invasive Bladder Cancer 5 2024-10-03
Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Ended

2023-504923-20-00 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer 5 2024-04-04
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic … Ended

2023-503655-10-00 Systemic Lupus Erythematosus (SLE). 5 2023-11-20
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A phase 3 study to Evaluate the Efficacy and Safety of HLX10 or placebo in Combination With Chemotherapy and Radiotherapy in Patients With L… Ended

2024-515047-31-00 Patients with Limited-Stage Small Cell Lung Cancer (LS- 5 2023-08-28
LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Atrial Fibrillation 5 2023-08-23
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Acute Ischemic Stroke and High-Risk Transient Ischemic 5 2023-08-04
HERMES – A research study to look at how ziltivekimab works compared to placebo in people with heart failure and inflammation. Ended

2022-501939-16-00 Heart failure (HF) with mildly reduced ejection fractio 5 2023-05-09
Pembrolizumab Monotherapy versus Sacituzumab Govitecan in Combination with MK‑3475 for PD-L1 TPS ≥50% Metastatic NSCLC Ended

2023-503501-11-00 Metastatic Non-small Cell Lung Cancer 5 2023-02-09